Hoth Therapeutics (Hoth Therapeutics) Cash-to-Debt : 168.95 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hoth Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 168.95.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Hoth Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Hoth Therapeutics's Cash-to-Debt or its related term are showing as below:

HOTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 168.95 Med: No Debt Max: No Debt
Current: 168.95

During the past 7 years, Hoth Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 168.95. And the median was No Debt.

HOTH's Cash-to-Debt is ranked better than
81.69% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs HOTH: 168.95

Hoth Therapeutics Cash-to-Debt Historical Data

The historical data trend for Hoth Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hoth Therapeutics Cash-to-Debt Chart

Hoth Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

168.95

Hoth Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	168.95

Competitive Comparison of Hoth Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Hoth Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hoth Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hoth Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Hoth Therapeutics's Cash-to-Debt falls into.

Hoth Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Hoth Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.292	/	(0.029	+	0.026)
	=	168.95

Hoth Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.292	/	(0.029	+	0.026)
	=	168.95

Hoth Therapeutics (NAS:HOTH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Hoth Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hoth Therapeutics (Hoth Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020

Website

https://www.hoththerapeutics.com

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Executives

Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie	director, officer: CEO and President	C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns	officer: Chief Scientific Officer	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes	director	1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc	10 percent owner	725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr	director	C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones	officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner	10 percent owner	44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor	10 percent owner	750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern	10 percent owner	20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023